Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis

Cited by (803)

Items 201–300 of 803

1. Cell‐penetrating peptide conjugates of indole‐3‐acetic acid‐based DNA primase/Gyrase inhibitors as potent anti‐tubercular agents against planktonic and biofilm culture of Mycobacterium smegmatis
   Rikeshwer Prasad Dewangan, Meenakshi Singh, Stefan Ilic, Benjamin Tam, Barak Akabayov · 2021 · Chemical Biology & Drug Design
2. Distribution patterns of drug resistance Mycobacterium tuberculosis among HIV negative and positive tuberculosis patients in Western Kenya
   Martin O. Ogwang, Mabel Imbuga, Caroline Wangare Ngugi, Lucy M. Mutharia, Gabriel N. Magoma, Lameck Oteko Diero · 2021 · BMC Infectious Diseases
3. De novo design of anti-tuberculosis agents using a structure-based deep learning method
   Sowmya Ramaswamy Krishnan, Navneet Bung, Siladitya Padhi, Gopalakrishnan Bulusu, Parimal Misra, Manojit Pal, Srinivas Oruganti, Rajgopal Srinivasan, Arijit Roy · 2022 · Journal of Molecular Graphics and Modelling
4. Computational screening of natural MtbDXR inhibitors for novel anti-tuberculosis compound discovery
   Sabrina Islam, Rahagir Salekeen, Ayesha Ashraf · 2023 · Journal of Biomolecular Structure and Dynamics
5. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment
   Cheng-Yu Kuo, Wen‐Hung Wang, Chung‐Hao Huang, Yen‐Hsu Chen, Po‐Liang Lu · 2017 · Journal of Microbiology Immunology and Infection
6. Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach
   Sita Sirisha Madugula, Selvaraman Nagamani, Esther Jamir, Lipsa Priyadarsinee, Garikapati Narahari Sastry · 2021 · Molecular Diversity
7. Review of the Effectiveness of Various Adjuvant Therapies in Treating Mycobacterium tuberculosis
   Arman Amin, Artin Vartanian, Aram Yegiazaryan, Abdul Latif Al-Kassir, Vishwanath Venketaraman · 2021 · Infectious Disease Reports
8. Evaluation of MTBDRplusand MTBDRslin Detecting Drug-Resistant Tuberculosis in a Chinese Population
   Wei Lu, Yan Feng, Jianming Wang, Limei Zhu · 2016 · Disease Markers
9. Tuberculosis: An Ongoing Global Threat
   Parissa Farnia, Ali Akbar Velayati, Jalaledin Ghanavi, Poopak Farnia · 2025 · Advances in experimental medicine and biology
10. Whole-genome sequencing reveals genotypic resistance in phenotypically susceptible Mycobacterium tuberculosis clinical isolates
    Zahra Hasan, Safina Abdul Razzak, Akbar Kanji, Sadia Shakoor, Rumina Hasan · 2023 · International Journal of Mycobacteriology
11. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review
    Swagatika Dash, Ekta Rathi, Avinash Kumar, Kiran Chawla, Alex Joseph, Suvarna G. Kini · 2023 · Journal of Biomolecular Structure and Dynamics
12. Dual-Target Mycobacterium tuberculosis Inhibition: Insights into the Molecular Mechanism of Antifolate Drugs
    Pritika Ramharack, Elliasu Yakubu Salifu, Clement Agoni · 2023 · International Journal of Molecular Sciences
13. Polycationic phosphorous dendrimer potentiates multiple antibiotics against drug-resistant mycobacterial pathogens
    Mohmmad Imran, Shriya Singh, Mohammad Naiyaz Ahmad, Pradip Malik, Atri Mukhopadhyay, Karan Singh Yadav, Umesh Datta Gupta, Madhav Nilakanth Mugale, Kalyan Mitra, Kishore Kumar Srivastava et al. · 2024 · Biomedicine & Pharmacotherapy
14. Characterization of isoniazid resistance and genetic mutations in isoniazid-resistant and rifampicin-susceptible Mycobacterium tuberculosis in China
    Dongxin Liu, Bing Zhao, Yang Zheng, Xichao Ou, Shengfen Wang, Yang Zhou, Yuanyuan Song, Hui Xia, Qiang Wei, Yanlin Zhao · 2024 · Infectious Medicine
15. A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management
    Aniket Patel, Aditya Pundkar, Anshu Agarwal, Charuta P Gadkari, Anmol K Nagpal, Nigil Kuttan · 2024 · Cureus
16. Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens
    Heba Mohammed Refat M. Selim, Fatma Alzahraa M. Gomaa, Mohammad Yahya Alshahrani, Radwa N. Morgan, Khaled M. Aboshanab · 2024 · Therapeutic Delivery
17. Exploring phytochemicals and marine natural products as alternative therapeutic agents targeting phosphotransacetylase (PTA) in Mycobacterium tuberculosis: An underexplored drug target
    Sneha Subramaniyan, Manikandan Jayaraman, Jeyaraman Jeyakanthan · 2025 · Journal of Molecular Graphics and Modelling
18. Structural insights into terminal arabinosylation of mycobacterial cell wall arabinan
    Yaqi Liu, Chelsea M. Brown, Satchal K. Erramilli, Yi-Chia Su, Shih-Yun Guu, Po‐Sen Tseng, Yu-Jen Wang, Nam Ha Duong, Piotr Tokarz, Brian Kloss et al. · 2025 · Nature Communications
19. Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours
    Buu Minh Tran, Jimmy Larsson, Anastasia Grip, Praneeth Karempudi, Johan Elf · 2025 · Nature Communications
20. Tuberculosis poor treatment outcomes and its determinants in Kilifi County, Kenya: a retrospective cohort study from 2012 to 2019
    Geoffrey G. Katana, Moses M. Ngari, Teresia Wamuyu Maina, Deche Sanga, Osman Abdikarim Abdullahi · 2022 · Archives of Public Health
21. Wang-OSO3H catalyzed one-pot sonochemical synthesis of 1,2,4-benzothiadiazine-1,1-dioxide derivatives: Their in silico / in vitro assessments against MtbCM
    Narender Addu, Hinuja Miriyala, Ravikumar Kapavarapu, Sunder Kumar Kolli, Manojit Pal · 2023 · Journal of Molecular Structure
22. Biapenem, a Carbapenem Antibiotic, Elicits Mycobacteria Specific Immune Responses and Reduces the Recurrence of Tuberculosis
    Isha Pahuja, Akanksha Verma, Antara Ghoshal, Suparba Mukhopadhyay, Anjna Kumari, Aishwarya Shaji, Shivam Chaturvedi, Ved Prakash Dwivedi, Ashima Bhaskar · 2023 · Microbiology Spectrum
23. Acyldepsipeptide Analogues: A Future Generation Antibiotics for Tuberculosis Treatment
    S.Z.Z. Cobongela, Maya Mellisa Makatini, Phumlane Selby Mdluli, Nicole Remaliah Samantha Sibuyi · 2022 · Pharmaceutics
24. mbtD and celA1 association with ethambutol resistance in Mycobacterium tuberculosis: A multiomics analysis
    Zhuhua Wu, Qiuchan Tan, Chenchen Zhang, Yuchuan Zhao, Qinghua Liao, Meiling Yu, Liuyue Xu, Jiawen Wang, Hongdi Liang, Haicheng Li et al. · 2022 · Frontiers in Cellular and Infection Microbiology
25. Mechanistic insights into the conformational changes and alterations in residual communications due to the mutations in the pncA Gene of Mycobacterium tuberculosis: A computational perspective for effective therapeutic solutions
    Manikandan Jayaraman, Rajalakshmi Kumar, Santhiya Panchalingam, Jeyaraman Jeyakanthan · 2024 · Computational Biology and Chemistry
26. Pangenome-wide association study reveals the selective absence of CRISPR genes (Rv2816c-19c) in drug-resistant Mycobacterium tuberculosis
    Nikhil Bhalla, Ranjan Kumar Nanda · 2024 · Microbiology Spectrum
27. Proteomics-based host-specific biomarkers for tuberculosis: The future of TB diagnosis
    Divya Pandey, Dipanjana Ghosh · 2024 · Journal of Proteomics
28. Formulation and optimisation of bedaquiline nanoemulsions for the potential treatment of multi drug resistant tuberculosis in paediatrics using quality by design
    Taiwo Oreoluwa Ajayi, Madan Poka, Bwalya Angel Witika · 2024 · Scientific Reports
29. Machine Learning‐Based High‐Throughput Screening, Molecular Modeling and Quantum Chemical Analysis to Investigate Mycobacterium tuberculosis MetRS Inhibitors
    Rajesh Maharjan, Kalpana Gyawali, Arjun Acharya, Madan Khanal, Kamal Khanal, Mohan Bahadur Kshetri, Madhav Prasad Ghimire, Tika Ram Lamichhane · 2025 · ChemistryOpen
30. Supradecoration induced homogenous electrochemical sensing: development of Ru( ii ) half sandwich complex as isoniazid and rifampicin dual sensor
    Mohd Mustafa, Tabee Jan, Mehdi Rohullah, Mubashir Hussain Masoodi, Noor U Din Reshi, Masood Ahmad Rizvi · 2025 · RSC Advances
31. Impact of socioeconomic factors on the treatment of tuberculosis
    Sukuru Chinna Reddy, Krishna Mohan, Keerti Jain · 2025 · Elsevier eBooks
32. Challenge to treat pre-extensively drug-resistant tuberculosis in a low-income country: A report of 12 cases
    Innocent Murhula Kashongwe, Fina Mawete, Nicole Anshambi, Nadine Maingowa, Murielle Aloni, Luc Losenga Lukasu, Michel Kayomo Kaswa, Zacharie Munogolo Kashongwe · 2020 · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
33. Identification of small molecules targeting homoserine acetyl transferase from Mycobacterium tuberculosis and Staphylococcus aureus
    Deepika Chaudhary, Avantika Singh, Mardiana Marzuki, Abhirupa Ghosh, Saqib Kidwai, Tannu Priya Gosain, Kiran Chawla, Sonu Kumar Gupta, Nisheeth Agarwal, Sudipto Saha et al. · 2022 · Scientific Reports
34. Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China
    Jin Zou, Shuyan Chen, Weiqiao Rao, Liang Fu, Jiancong Zhang, Yunli Liao, Ying Zhang, Ning Lv, Guofang Deng, Shijin Yang et al. · 2022 · Antimicrobial Agents and Chemotherapy
35. Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c
    Christy Rosaline Nirmal, Sam Ebenezer Rajadas, Mahizhaveni Balasubramanian, Divya Magdaline, Naresh Babu Chilamakuru, Rajkumar Dinesh, Ammayappan Radhakrishnan, Ramalingam Paraman, Rajesh Kumar Mondal, Azger Dusthackeer · 2023 · International Journal of Microbiology Research
36. Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality?
    Carola Oelofse, Carene Anne Alene Ndong Sima, Marlo Möller, Caitlin Uren · 2023 · Clinical and Translational Science
37. Discovery of new naphthyridine hybrids against enoyl-ACP reductase (inhA) protein target of Mycobacterium tuberculosis: Molecular docking, molecular dynamics simulations studies
    Govindaraj Sabarees, Vadivel Velmurugan, Viswas Raja Solomon · 2023 · Chemical Physics Impact
38. The Targeted Maximum Likelihood estimation to estimate the causal effects of the previous tuberculosis treatment in Multidrug-resistant tuberculosis in Sudan
    Adel Hussein Elduma, Kourosh Holakouie‐Naieni, Amir Almasi‐Hashiani, Abbas Rahimi Foroushani, Hamdan Mustafa Hamdan Ali, Muatsim Ahmed Mohammed Adam, Asma Elsony, Mohammad Alì Mansournia · 2023 · PLoS ONE
39. Line Probe Assay Test in New Cases of Tuberculosis with Rifampicin Resistance not Detected by Xpert MTB/RIF
    Soedarsono Soedarsono, Ni Made Mertaniasih, Helmia Hasan, Tutik Kusmiati, Ariani Permatasari, Deby Kusumaningrum, Whendy Wijaksono · 2022 · International Journal of Mycobacteriology
40. Effects of Everolimus in Modulating the Host Immune Responses against Mycobacterium tuberculosis Infection
    Anmol Raien, Sofia Davis, Michelle H. Zhang, David Zitser, Michelle Lin, Graysen Pitcher, Krishna Bhalodia, Selvakumar Subbian, Vishwanath Venketaraman · 2023 · Cells
41. Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy
    Mehmood Qadir, Rani Faryal, Muhammad Tahir Khan, Sajjad Ahmed Khan, Shulin Zhang, Weimin Li, Dong Qing Wei, Sabira Tahseen, Timothy Daniel McHugh · 2023 · Microbiology Spectrum
42. Antitubercular evaluation of dihydropyridine–triazole conjugates: design, synthesis, in vitro screening, SAR and in silico ADME predictions
    Ajay Kishor Kushawaha, Arvind Kumar Jaiswal, Jay Gupta, Sarita Katiyar, Alisha Ansari, Hemlata Bhatt, Sandeep Sharma, Abhijit Deb Choudhury, Rabi Sankar Bhatta, Bhupendra Narain Singh et al. · 2024 · RSC Medicinal Chemistry
43. Unearthing phytochemicals as natural inhibitors for pantothenate synthetase in Mycobacterium tuberculosis: A computational approach
    Mandeep Chouhan, Prashant Kumar Tiwari, Richa Mishra, Saurabh K. Gupta, Mukesh Kumar, Eman Abdullah Almuqri, Nasir A. Ibrahim, Nosiba S. Basher, Anis Ahmad Chaudhary, Vivek Dhar Dwivedi et al. · 2024 · Frontiers in Pharmacology
44. Clinical best practices for caring for people with expanded resistance to newer TB drugs
    Tendai Nkomo, Zarir Farokh Udwadia, Debrah Vambe, Annelies Van Rie, Sein Sein Thi, Jonathan Stillo, Assel T. Stambekova, A. Sinha, Michael Rich, Anja Reuter et al. · 2025 · IJTLD OPEN
45. Mycobacterium tuberculosis Rv2005c Induces Dendritic Cell Maturation and Th1 Responses and Exhibits Immunotherapeutic Activity by Fusion with the Rv2882c Protein
    Yong Woo Back, Ki Won Shin, Seunga Choi, Hye‐Soo Park, Kang-In Lee, Han‐Gyu Choi, Hwa‐Jung Kim · 2020 · Vaccines
46. Delayed care-seeking and its underlying factors among patients with tuberculosis in Yangon, Myanmar
    May Chan Oo, Kyaw Zarni Tun, Kyaw Ko Ko, Pyae Linn Aung · 2020 · The Journal of Infection in Developing Countries
47. Identification of Mycobacterium tuberculosis Antigens with Vaccine Potential Using a Machine Learning-Based Reverse Vaccinology Approach
    Blaine Teahan, Edison Ong, Zhenhua Yang · 2021 · Vaccines
48. Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies
    Putu Nandika Tungga Yudanti Mahardani, Dyah Kanya Wati, Azriel Siloam, Ni Putu Ayu Savitri, Arya Krisna Manggala · 2021 · Oman Medical Journal
49. Brazilian cohort study of risk factors associated with unsuccessful outcomes of drug resistant tuberculosis
    Patrícia Bartholomay, Rejane Sobrino Pinheiro, Fernanda Dockhorn Costa Johansen, Daniele Maria Pelissari, Wildo Navegantes de Araújo · 2021 · BMC Infectious Diseases
50. NSC19723, a Thiacetazone-Like Benzaldehyde Thiosemicarbazone Improves the Efficacy of TB Drugs In Vitro and In Vivo
    Padam Singh, Srishti Rawat, Ashish Kumar Agrahari, Manisha Singh, Saurabh Chugh, Sudagar S. Gurcha, Albel Singh, Katherine A. Abrahams, Gurdyal Singh Besra, Shailendra Asthana et al. · 2022 · Microbiology Spectrum
51. Review canine tuberculosis – An emerging concern
    Emi Barker, Conor O’Halloran, Danièlle Audry Gunn-Moore · 2024 · The Veterinary Journal
52. Burden of baseline resistance of Mycobacterium tuberculosis to fluoroquinolones and second-line injectables in central India
    Prabha Desikan, Nikita Panwalkar, Shreya Chaudhuri, Zeba Khan, Ram Prakash Punde, Ankur Pauranik, Shaina Beg Mirza, Rajeev Ranjan, Sridhar Anand, K.S. Sachdeva · 2020 · Transactions of the Royal Society of Tropical Medicine and Hygiene
53. Understanding how geographic, demographic and treatment history impact health outcomes of patients with multi-drug-resistant tuberculosis in Pakistan, 2014–2017
    Farwah Iqbal, Miranda K. Defer, A. Latif, H. Hadi · 2020 · Epidemiology and Infection
54. Functional Characterization of the γ-Aminobutyric Acid Transporter from Mycobacterium smegmatis MC 2 155 Reveals Sodium-Driven GABA Transport
    Ana Pavić, Yurui Ji, Agnese Serafini, Acely Garza-Garcı́a, Martin J. McPhillie, Alexandra O. M. Holmes, Luiz Pedro S. de Carvalho, Yingying Wang, Mark G. Bartlam, Adrian Goldman et al. · 2020 · Journal of Bacteriology
55. Label-Free Comparative Proteomics of Differentially Expressed Mycobacterium tuberculosis Protein in Rifampicin-Related Drug-Resistant Strains
    Nadeem Ullah, Ling Hao, Jo‐Lewis Banga Ndzouboukou, Shiyun Chen, Yaqi Wu, Longmeng Li, Eman Borham Mohamed, Yangbo Hu, Xionglin Fan · 2021 · Pathogens
56. Mycobacterial Lineages Associated with Drug Resistance in Patients with Extrapulmonary Tuberculosis in Addis Ababa, Ethiopia
    Getu Diriba, Abebaw Kebede, Habteyes Hailu Tola, Ayinalem Alemu, Bazezew Yenew, Shewki Moga, Desalegn Addise, Zemedu Mohammed, Muluwork Getahun, Mengistu Fantahun et al. · 2021 · Tuberculosis Research and Treatment
57. Plant-Associated Endophytic Fungi and Its Secondary Metabolites Against Drug-Resistant Pathogenic Microbes
    Sriravali Karnam, Anil B. Jindal, Bhim Pratap Singh, Atish T. Paul · 2022 · Springer eBooks
58. Synthesis, Optical Properties, Preliminary Antimycobacterial Evaluation and Docking Studies of Trifluoroacetylated 3‐Pyrrolyl Boron‐Dipyrromethene
    Matvey S. Horetski, Anna M. Gorlova, Renata Płocińska, Anna M. Brzostek, Yaroslav V. Faletrov, Jarosław Dziadek, V. M. Shkumatov · 2022 · ChemistrySelect
59. Targeting caseinolytic protease P and its AAA1 chaperone for tuberculosis treatment
    Xin Xu, Laiying Zhang, Tao Yang, Zhiqiang Qiu, Lang Bai, Youfu Luo · 2023 · Drug Discovery Today
60. The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model
    Jennie Ruelas Castillo, Pranita Neupane, Styliani Karanika, Stefanie Krug, Darla Quijada, Andrew Jesse Garcia, Samuel K. Ayeh, Addis Yilma, Diego Luís Costa, Alan Sher et al. · 2023 · Antimicrobial Agents and Chemotherapy
61. Molecular Analysis of Streptomycin Resistance Genes in Clinical Strains of Mycobacterium tuberculosis and Biocomputational Analysis of the MtGidB L101F Variant
    Álvaro Rodríguez-García, Rosa E. Mares‐Alejandre, Patricia L. A. Muñoz-Muñoz, Samuel Ruvalcaba-Ruiz, Ricardo González-Sánchez, Johanna Bernáldez-Sarabia, Samuel G. Meléndez-López, Alexei F. Licea-Navarro, Marco A. Ramos · 2021 · Antibiotics
62. Design and characterisation of piperazine-benzofuran integrated dinitrobenzenesulfonamide as Mycobacterium tuberculosis H37Rv strain inhibitors
    Vallabhaneni S. Murthy, Yasinalli Tamboli, Vagolu Siva Krishna, Dharmarajan Sriram, Siddique Akber Ansari, Abdullah A. Alarfaj, Abdurahman Hajinur Hirad, Vijayaparthasarathi Vijayakumar · 2021 · Journal of Enzyme Inhibition and Medicinal Chemistry
63. Development and Characterization of Linezolid loaded Biocompatible Solidlipid based Nanocarrier for Enhanced Lung Deposition and Anti-tubercular Activity: Next Generation tailor-made Carrier for Dry Powder Inhaler
    Ravindra N. Kamble, Eram Kausar, Madhugandha S. Kawadiwale, Ashwin Mali · 2023 · Current Indian Science
64. Molecular docking-based interaction studies on imidazo[1,2-a] pyridine ethers and squaramides as anti-tubercular agents
    Sarfaraz Ahmed, Arulsamy Elphine Prabahar, Anil Kumar Saxena · 2023 · SAR and QSAR in environmental research
65. Phenotypic and genotypic drug susceptibility patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Central and Southern Ethiopia
    Melaku Tilahun, Teklu Wegayehu, Biniam Wondale, Tewodros Tariku Gebresilase, Tesfaye Gebreyohannes, Abraham Tekola Gebremedhn, Mekdes Alemu Tola, Sebsib Neway, Bethlehem Adnew, Maeruf Fetu Nassir et al. · 2023 · PLoS ONE
66. VIRTUAL SCREENING OF FDA-APPROVED DRUGS BY MOLECULAR DOCKING AND DYNAMICS SIMULATION TO RECOGNIZE POTENTIAL INHIBITORS AGAINST MYCOBACTERIUM TUBERCULOSIS ENOYL-ACYL CARRIER PROTEIN REDUCTASE ENZYME
    Hasanain Abdulhameed Odhar, Ahmed Fadhil Hashim, Salam Waheed Ahjel, Suhad Sami Humadi · 2024 · International Journal of Applied Pharmaceutics
67. Applications of Inorganic Nanomaterials against Tuberculosis: A Comprehensive Review
    Debabrata Ghosh Dastidar, Arnab Roy, Gourav Ghosh, Supratim Mandal · 2024 · Current Drug Delivery
68. Anti-mutagenic agent targeting LexA to combat antimicrobial resistance in mycobacteria
    Chitral Chatterjee, Gokul Raj Mohan, Hariharan Vedi Chinnasamy, Bhumika Biswas, Vidya Sundaram, Ashutosh Srivastava, Saravanan Matheshwaran · 2024 · Journal of Biological Chemistry
69. Palladium immobilized on functionalized halloysite: A robust catalyst for ligand free Suzuki–Miyaura cross coupling and synthesis of pyrano[2,3-c]pyrazole motifs via four component cascade reaction and their in-silico antitubercular screening
    Pawan Kumar, Sakshi Panhotra, Muskan Muskan, Avtar Changotra, Sneh Lata, Ankit Mehta, Tamaghna Maitra, Princy Gupta · 2024 · Applied Catalysis A General
70. Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentration of rifampicin
    Arti Shrivas, Sarman Singh, Jitendra Singh, Prem Shankar, Payal Soni, Syed Beenish Rufai, Anand Kumar Maurya, Shashank Purwar · 2025 · Microbiology Spectrum
71. Host-Directed Therapies Based on Protease Inhibitors to Control Mycobacterium tuberculosis and HIV Coinfection
    Manoj Mandal, David Pires, José Miguel Azevedo‐Pereira, Elsa Anes · 2025 · Microorganisms
72. Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends
    Gautam Kumar, Priya Mondal, Amit Kadam, Isha Dhamija, Ravindra Pal Singh, Deepak Nathiya, Sandeep Kumar · 2025 · BIO Integration
73. Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry
    N. Wlodarchak, John B. Feltenberger, Zheng-Qin Ye, Jeffrey Beczkiewicz, Rebecca R. Procknow, Gang Yan, T. King, Jennifer E. Golden, R. Striker · 2021 · ACS Medicinal Chemistry Letters
74. Identification of Mycobacterium tuberculosis in Pulmonary and Extrapulmonary Specimens of Iranian Hospitalized Patients During 2017–2021
    Mohammadreza Salehi, Reza Shahsiah, Kiarash Mohammad Khorasani, Malihe Hasannezhad, Arian Rahimi, Bahare Yousefi, Amir Aliramezani · 2023 · International Journal of Mycobacteriology
75. Computational study on Schiff base derived salicylaldehyde and furfuraldehyde derivatives as potent anti-tubercular agents: prospect to dihydropteroate synthase inhibitors
    Chita Ranjan Sahoo, Sudhir Kumar Paidesetty, Budheswar Dehury, Rabindra N. Padhy · 2023 · Journal of Biomolecular Structure and Dynamics
76. Quantum chemical studies, spectroscopic NMR and FT-IR analysis, and molecular docking investigation of 3,3′-di-O-methyl ellagic acid (DMA) as a potent Mycobacterium tuberculosis agent
    Musa Runde, Mohammed Hassan Shagal, Anna Imojara, Elizabeth Nkagafel Mbim, Uwamere O. Edeghor, Moses M. Edim, Bernard C. Okoro, Amanda-Lee Ezra Manicum, Hitler Louis · 2023 · Results in Chemistry
77. Efflux pump gene single-nucleotide variants associated with resistance in Mycobacterium tuberculosis isolates with discrepant drug genotypes
    Zahra Hasan, Safina Abdul Razzak, Akbar Kanji, Sadia Shakoor, Rumina Hasan · 2024 · Journal of Global Antimicrobial Resistance
78. Design, Synthesis and Biological Evaluation of Ethyl 5‐(1‐benzyl‐1H‐indol‐5‐yl) Isoxazole‐3‐Carboxylates as Antimycobacterial Agents
    Rani Bandela, Santosh Kumar Sahoo, Atri Mukhopadhyay, Mohmmad Imran, Anuradha Singampalli, Sarvan Maddipatla, Sri Mounika Bellapukonda, Devdhar Panchal, Srinivas Nanduri, Arunava Dasgupta et al. · 2024 · ChemMedChem
79. Potential Genes Related to Levofloxacin Resistance in Mycobacterium tuberculosis Based on Transcriptome and Methylome Overlap Analysis
    Haicheng Li, Huixin Guo, Tao Chen, Wei Wang, Zhuhua Wu, Liang Chen, Huizhong Wu, Gaopo Xu, Xun-xun Chen, Lin Zhou · 2020 · Journal of Molecular Evolution
80. Understanding the gaps in elimination of tuberculosis in India
    Khushali Vashi, Yashwant Vishnupant Pathak, Jasmin Patel · 2020 · Indian Journal of Tuberculosis
81. Targeted genome sequencing for tuberculosis drug susceptibility testing in South Africa: a proposed diagnostic pipeline
    Tayarv Bagratee, David John Studholme · 2024 · Access Microbiology
82. Tuberculosis Vaccines
    Willem Albert Hanekom, Thomas R. Hawn, Ann M. Ginsberg · 2017 · Elsevier eBooks
83. In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients
    Ruoyan Ying, Xiaochen Huang, Yaxian Gao, Jie Wang, Yidian Liu, Wei Sha, Hua Yang · 2021 · Infection and Drug Resistance
84. Tuberculosis meningitis coexisting with HIV Infection: a comprehensive review
    Inesa Navasardyan, Alexander Abdou, Samuel Kades, Yura Misakyan, Jacob Ochsner, Selvakumar Subbian, Vishwanath Venketaraman · 2023 · Frontiers in Tuberculosis
85. Targeting of essential mycobacterial replication enzyme DnaG primase revealed Mitoxantrone and Vapreotide as novel mycobacterial growth inhibitors**
    Waseem Ali, Salma Jamal, Rishabh Gangwar, Faraz Ahmed, Rahul Sharma, Meetu Agarwal, Javaid Ahmad Sheikh, Abhinav Grover, Sonam Grover · 2023 · Molecular Informatics
86. Revolutionizing Tuberculosis Management With Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas Technology: A Comprehensive Literature Review
    Achal Shetty, Hamida Kwas, Hayfa Rajhi, Harish Rangareddy, Jessica Fryer · 2024 · Cureus
87. Mycobacterium tuberculosis exploits SIRT2 to trap iron for its intracellular survival
    Sharmila Talukdar, Radheshyam Modanwal, Gaurav Kumar Chaubey, Asmita Dhiman, Rahul Dilawari, Chaaya Iyengar Raje, Manoj Raje · 2024 · Free Radical Biology and Medicine
88. Ionic liquid promoted facile one-pot synthesis of phenothiazine-thiazolidin-4-ones as potent antitubercular agents via mycobacterial ATP synthase inhibition
    Rajkumar Reddyrajula, Umadevi Etikyala, Harish Chandra Mahapathra, Rai Adesh Udaybhan, Vijjulatha Manga, Udayakumar Dalimba · 2024 · Journal of Molecular Structure
89. Pharmaceutical Cocrystals and Salt of Ethionamide with Fluorobenzoic Acids for Improved Drug Delivery
    Naveena S. Veeranagaiah, Madhu Rana, Battini Swapna, Pallepogu Raghavaiah, Ashwini Kumar Nangia · 2024 · Crystal Growth & Design
90. Vic9 mycobacteriophage: the first subcluster B2 phage isolated in Russia
    Marina V. Zaychikova, Maja V. Malakhova, Dmitry Bespiatykh, Maria A. Kornienko, Ksenia M. Klimina, Aleksandra A. Strokach, Roman B. Gorodnichev, Arina German, Mikhail V. Fursov, Dmitry V. Bagrov et al. · 2025 · Frontiers in Microbiology
91. Targeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives
    Mohamad Mosa Mubarak, Hadiya Amin Kantroo, Firdoous Ahmad Mir, Chetan Kumar, Zahoor Ahmad · 2025 · Archives of Microbiology
92. Vitamin D3 loaded polycaprolactone nanoparticles enhance the expression of the antimicrobial peptide cathelicidin in macrophages
    Prince N. Dlozi, Rami Ahmed, Star Khoza, Admire Dube · 2025 · Artificial Cells Nanomedicine and Biotechnology
93. Tuberculosis drug development; fluoroquinolone structural tailoring
    Alicia M Gutiérrez-Mauricio, Juan Valentín Trujillo-Páez, Luis Alberto Trejo-Martinez, Bruno Tonatiuh Rivas-Santiago, Paola Pérez-García, Saúl Noriega, Juan Ernesto López-Ramos, Jaime Cardoso‐Ortiz, Adrián Rodríguez-Carlos · 2025 · The Journal of Antibiotics
94. Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB
    Natalia Zaporojan, Ramona Hodișan, Carmen Pantiș, Andrei Nicolae Csep, Claudiu Zaporojan, Dana Carmen Zaha · 2025 · Antibiotics
95. Overcoming Treatment Challenges in HIV-Associated Mycobacterial Diseases: New Therapeutic Frontiers
    Omid Nikjeh, S D Rejali, Kayvan Sasaninia, Vishwanath Venketaraman · 2025 · International Journal of Molecular Sciences
96. Drug-resistance and its impact on cutaneous tuberculosis
    V. Ramesh, Adhyatm Bhandari, Rahul Mahajan · 2022 · Indian Dermatology Online Journal
97. Anti-Mycobacterial Activity of Flavonoid and Pyrimidine Compounds
    Saurabh Garg, Rakesh K. Kumar, Dennis Y. Kunimoto, Gina R. Rayat · 2022 · Molecules
98. Profiling of 3-Formyl rifamycin (3-FR) from sintered fixed dose combinations (SDC) of rifampicin and isoniazid by using RP-HPLC, LC-ESI-QTOF and UPLC/MS/MS
    Tukaram Ram Karanwad, Sachin B. Jorvekar, Santa Mandal, Roshan M. Borkar, Subham Banerjee · 2023 · Microchemical Journal
99. Small Peptide Conjugates of Benzothiazole‐2‐Carboxylic Acids Targeting DprE1 Against Tuberculosis
    Rabiya Samoon, Shashikanta Sau, Arif O. Khan, Insha Latief, Nitin Pal Kalia, Malik Zainul Abdin, Syed Shafi · 2024 · ChemistrySelect
100. Delamanid proliposomal powder aerosols targeting alveolar macrophages for treatment of pulmonary extensively drug-resistant tuberculosis treatment: Bioactivity, biocompatibility, and structure elucidation
     Krittawan Tongkanarak, Himanshu Paliwal, Titpawan Nakpheng, Muhammad Ali Khumaini Mudhar Bintang, Teerapol Srichana · 2024 · Journal of Drug Delivery Science and Technology